TrialSignal transduction and targeted therapy2026

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.

Shuang Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.